CTLT's solid segmental results led to an encouraging fiscal first-quarter performance, driving share prices in after-hours ...

Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...

The contract manufacturer fell short of Wall Street’s projections for its first quarter of fiscal 2025, which ended Sept. 30, ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Catalent Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information Catalent Inc presented to its investors. Catalent Inc., a leading global contract development and ...

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 ...

EU antitrust regulators to decide on Novo Holdings' Catalent buy by Dec. 6 Novo announced $16.5 billion acquisition in February Novo Nordisk seeking to boost output of Wegovy weight-loss drug ...